The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
#EHA2024: Longer-term follow-up, patient outcomes, and real-world findings in multiple myeloma
Mohamad Mohty
Philippe Moreau
Bruno Paiva
Leo Rasche
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to longer-term follow-up, patient outcomes and real-world findings in multiple myeloma here.
CONGRESS | POSTER | #EHA2024 | Julia Mersi presented findings on the spectrum and duration of infectious complications in patients treated with BCMA- and GPRC5D-targeted immunotherapies in MM, N=137. Different patterns of frequency and duration were observed. #mmsm #myeloma… pic.twitter.com/FjmxGP2qjZ
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Katarina Uttervall discusses longer-term follow-up of patients with RRMM receiving prophylactic tocilizumab (n=24) for reduction of CRS in the phase I/II MAJESTEC-1 study. Prophylactic tocilizumab reduced Grade 1/2 CRS from 72.1 to 25%. #mmsm… pic.twitter.com/xPkoumpkNL
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Mohamad Mohty @Mohty_EBMT shares long-term survival outcomes from the phase II MagnetisMM-3 study of elranatamab in patients with RRMM, N=123. ORR remained at 61%, with median DoR not reached. #mmsm #myeloma #MedicalCongress pic.twitter.com/FDjz9FIgSb
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Leo Rasche @RascheLeo shares long-term efficacy and safety results from the phase I/II MONUMENTAL-1 study of talquetamab (TAL) in patients with RRMM, N=375. ORR ≥70% in TCR-naïve and 67% in prior TCR. #mmsm #myeloma #MedicalCongress pic.twitter.com/n6udlYNyn3
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Sharlene Dong @sharlenedong discusses real-world carfilzomib (K) prescribing patterns and outcomes for patients with RRMM, N=2420. Once-weekly K dosing is now SoC; higher doses/frequencies were not associated with improved outcomes vs weekly K… pic.twitter.com/fLC5636zCO
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Saad Usmani @szusmani @MSKCancerCenter shares findings from a real-world schedule de-escalation of teclistamab (TEC) in patients with RRMM, N=86. Despite a high-risk patient population, TEC demonstrated a 61% ORR, comparable to MajesTEC-1. #mmsm… pic.twitter.com/d7I5iDRSf1
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS #EHA2024 | Presidential Session | @BrunoPaiva_UNA @ClinicaNavarra @CIMA_unav @idisnanavarra provides an insightful discussion on innovative tools for disease monitoring in #MultipleMyeloma. They discuss current disease monitoring strategies and potential future… pic.twitter.com/bQpDHiVImE
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS #EHA2024 | Sarah Cayla, @univ_paris_cite highlights an analysis of outcomes of patients with R/R MM following early progression after ide-cel therapy using the DESCAR-T database. Patients who relapsed after ide-cel had poor outcomes, even with the use of bispecific… pic.twitter.com/BRugytJne0
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS #EHA2024 | Philippe Moreau, @CHUnantes presents long-term outcomes from the phase III CASSIOPEIA trial of D-VTd followed by DARA maintenance in transplant-eligible patients with NDMM. D-VTd induction and consolidation plus DARA maintenance resulted in the most pronounced… pic.twitter.com/WoZ4aEgQBW
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content